The U.S. Food and Drug Administration (FDA) has announced a voluntary nationwide recall of more than half a million bottles of the blood pressure medication prazosin hydrochloride. The recall was initiated due to concerns that the medication may contain a cancer-causing chemical.
New Jersey-based Teva Pharmaceuticals USA, along with drug distributor Amerisource Health Services, issued the recall earlier this month. The affected recall involves over 580,000 bottles of prazosin capsules in various strengths, according to the FDA.
Prazosin is commonly prescribed by doctors to help lower blood pressure by relaxing blood vessels. Additionally, it is sometimes used to treat nightmares and other sleep disturbances related to post-traumatic stress disorder (PTSD).
The FDA has classified the affected lots of prazosin with a Class II risk classification. This decision was based on the presence of nitrosamine impurities found in some of the recalled medication. Nitrosamines are a class of chemicals that are considered potentially cancer-causing.
According to the FDA, N-nitrosamine impurities can form during the manufacturing or storage processes of a drug, raising concerns about patient safety. The agency continues to monitor the situation closely and advises patients to consult their healthcare providers if they have any questions or concerns regarding the medication.
https://www.chicagotribune.com/2025/10/31/prazosin-recall/
